
RELEASE

GENFIT Answers Investors' Questions Raised Today

Lille (France), Cambridge (Massachusetts, United States), January 23, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today reacts to unsubstantiated speculation.

In reaction to certain investors' concerns over unusually large trading volumes in the Company's shares and unsubstantiated rumors circulating on several channels today, GENFIT indicates that the RESOLVE-IT trial is progressing as planned. GENFIT also reiterates that top line interim RESOLVE-IT Phase 3 data are still unknown as of today, that they will be disclosed before the end of Q1 2020, as previously announced, and that there is no other material information about the Company to be communicated at this stage.

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com